Alexander Abitbol

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

<scp>IMpact</scp> of flash glucose Monitoring in <scp>pEople</scp> with type 2 Diabetes Inadequately controlled with non‐insulin Antihyperglycaemic <scp>ThErapy</scp> ( <scp>IMMEDIATE</scp> ): A randomized controlled trial

Ronnie Aronson, Ruth E. Brown, Lisa Chu et al. · Diabetes Obesity and Metabolism · 2022 · 98 citations · Full text

The impact of flash glucose monitoring on glycated hemoglobin in type 2 diabetes managed with basal insulin in Canada: A retrospective real-world chart review study

Tom Elliott, Sorin Beca, Rajendra Beharry et al. · Diabetes and Vascular Disease Research · 2021 · 45 citations · Full text

AWAREness of Diagnosis and Treatment of Chronic Kidney Disease in Adults With Type 2 Diabetes (AWARE-CKD in T2D)

Lisa Chu, Sanjit K. Bhogal, Peter Lin et al. · Canadian Journal of Diabetes · 2022 · 38 citations · Full text